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Objectives The purpose of this study was to determine the consistency of the effects of radial artery access in patients with
ST-segment elevation myocardial infarction (STEMI) and in those with non–ST-segment elevation acute coronary
syndrome (NSTEACS).
Background The safety associated with radial access may translate into mortality benefit in higher-risk patients, such as
those with STEMI.
Methods We compared efficacy and bleeding outcomes in patients randomized to radial versus femoral access in RIVAL
(RadIal Vs femorAL access for coronary intervention trial) (N  7,021) separately in those with STEMI (n 
1,958) and NSTEACS (n  5,063). Interaction tests between access site and acute coronary syndrome type were
performed.
Results Baseline characteristics were well matched between radial and femoral groups. There were significant interac-
tions for the primary outcome of death/myocardial infarction/stroke/non–coronary artery bypass graft–related
major bleeding (p  0.025), the secondary outcome of death/myocardial infarction/stroke (p  0.011) and
mortality (p  0.001). In STEMI patients, radial access reduced the primary outcome compared with femoral
access (3.1% vs. 5.2%; hazard ratio [HR]: 0.60; p  0.026). For NSTEACS, the rates were 3.8% and 3.5%, re-
spectively (p  0.49). In STEMI patients, death/myocardial infarction/stroke were also reduced with radial ac-
cess (2.7% vs. 4.6%; HR 0.59; p  0.031), as was all-cause mortality (1.3% vs. 3.2%; HR: 0.39; p  0.006), with
no difference in NSTEACS patients. Operator radial experience was greater in STEMI versus NSTEACS patients
(400 vs. 326 cases/year, p  0.0001). In primary PCI, mortality was reduced with radial access (1.4% vs. 3.1%;
HR: 0.46; p  0.041).
Conclusions In patients with STEMI, radial artery access reduced the primary outcome and mortality. No such benefit was
observed in patients with NSTEACS. The radial approach may be preferred in STEMI patients when the operator
has considerable radial experience. (A Trial of Trans-radial Versus Trans-femoral Percutaneous Coronary Interven-
tion (PCI) Access Site Approach in Patients With Unstable Angina or Myocardial Infarction Managed With an In-
vasive Strategy [RIVAL]; NCT01014273) (J Am Coll Cardiol 2012;60:2490–9) © 2012 by the American College of
Cardiology Foundation
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December 18, 2012:2490–9 Radial Versus Femoral Artery Access in STEMIAn invasive strategy including percutaneous coronary interven-
tion (PCI) improves clinical outcomes in patients with ST-
segment elevation myocardial infarction (STEMI) and in
high-risk patients with non–ST-segment elevation acute cor-
onary syndromes (NSTEACS) (1,2). However, because these
patients are also treated with multiple antithrombotic and
antiplatelet therapies, they are at increased risk of bleeding
complications. Bleeding has been linked with higher mortality
in several large observational studies (3–5). Randomized trials
have suggested that antithrombotic treatments with fewer
bleeding complications may lead to improved longer-term
clinical outcomes, including mortality (6–8). In observational
tudies of patients undergoing PCI, radial artery access reduced
ccess site–related bleeding compared with femoral artery
ccess (9–12), and in some studies, this benefit was strongly
ssociated with improvements in mortality (13–16). However,
hese observational studies are limited by unmeasured con-
ounding and selection bias; there have been very few random-
zed trials to adequately evaluate this relationship.
See page 2500
RIVAL (A Trial of Trans-radial Versus Trans-femoral
Percutaneous Coronary Intervention (PCI) Access Site
Approach in Patients With Unstable Angina or Myocardial
Infarction Managed With an Invasive Strategy) was a
multinational randomized trial involving 7,021 patients
with either NSTEACS or STEMI that tested the hypoth-
esis that a radial artery approach would reduce bleeding and
major cardiovascular events compared with a femoral approach
(17). There was no significant difference in the primary
composite outcome of death, myocardial infarction (MI),
stroke or non–coronary artery bypass graft (CABG) –related
major bleeding, although there was a substantial reduction
in major vascular access site complications favoring the
radial approach. However, patients with STEMI differ from
those with NSTEACS because they are exposed to more
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accepted July 24, 2012.potent antithrombotic therapies,
have higher risk-adjusted rate of
bleeding complications (18), and
undergo PCI with much higher
frequency than patients with
NSTEACS. We therefore hy-
pothesized that there might be
differences in treatment effect of
radial versus femoral artery access
site in patients with STEMI and
NSTEACS enrolled in RIVAL.
Methods
Study design and patients. RI-
VAL was a randomized, parallel-
group, multicenter trial of radial
versus femoral access site inter-
vention (17). The study protocol
was previously reported (19,20). Briefly, patients were in-
cluded if they had either STEMI or NSTEACS and a
planned invasive approach, and the interventional cardiolo-
gist was willing to proceed with either radial or femoral
access (and had expertise in both, including at least 50 radial
procedures within the previous year). Patients were required
to have intact dual circulation of the hand as assessed by an
Allen’s test. Patients were ineligible if they had cardiogenic
shock, severe peripheral vascular disease precluding a fem-
oral approach, or previous coronary bypass surgery with an
internal mammary artery graft. The study was approved by
all appropriate national regulatory authorities and the ethics
committees of participating centers. All patients provided
written informed consent to participate before enrollment.
Patients were randomly assigned to radial or femoral
access by a 24-h computerized, central automated voice
response system. This pre-specified analysis of the trial
evaluates outcomes separately in patients with a pre-
randomization diagnosis of STEMI or NSTEACS.
STEMI patients were defined as those presenting with
ischemic symptoms 20 min with ST-segment elevation of
2 mm in 2 contiguous pre-cordial leads or 1 mm in 2
contiguous limb leads or new left bundle branch block.
Patients with NSTEACS were required to have unstable
ischemic symptoms and electrocardiographic changes com-
patible with new ischemia or increased cardiac biomarkers.
Patients 60 years of age and younger with normal cardiac
biomarkers were also eligible if they had documented
evidence of coronary artery disease. The primary efficacy
outcome of RIVAL was the occurrence of death, myocardial
infarction, stroke, or non-CABG–related major bleeding
within 30 days. Key secondary outcomes were: 1) death,
myocardial infarction, or stroke; and 2) non-CABG–related
major bleeding at 30 days. Other secondary outcomes
included components of the primary outcome and major
Abbreviations
and Acronyms
CABG  coronary artery
bypass graft
HR  hazard ratio
MI  myocardial infarction
NSTEACS  non–ST-
segment elevation acute
coronary syndrome
NSTEMI  non–ST-segment
elevation myocardial
infarction
PCI  percutaneous
coronary intervention
STEMI  ST-segment
elevation myocardial
infarctionvascular access site complications.
a
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(19,20). In brief, major bleeding was defined as bleeding
that 1) was fatal; 2) resulted in transfusion of 2 units of
blood; 3) caused substantial hypotension with the need for
inotropes; 4) needed surgical intervention; 5) caused severely
disabling sequelae; 6) was intracranial and symptomatic or
intraocular and led to significant visual loss; or 7) led to a
decrease in hemoglobin of at least 50 g/l. ACUITY (Acute
Catheterization and Urgent Intervention strategy) non-
CABG–related major bleeding was defined as RIVAL
major bleeding, large hematomas (greater than what would
be normally be expected), and pseudoaneurysms requiring
intervention. Minor bleeding was defined as bleeding events
that did not meet the criteria for a major bleed and required
transfusion of 1 unit of blood or modification of the drug
regimen (i.e., cessation of antiplatelet or antithrombotic
therapy). Major vascular access site complications included a
pseudoaneurysm needing closure, a large hematoma, an
arteriovenous fistula, or an ischemic limb needing surgery.
These complications were classified as a major bleeding
event only they also met the above definition of major
bleeding.
Statistical analyses. Categorical variables in each cohort
nd between cohorts were compared by the chi-square test
nd continuous variables by the Student t test (for normally
Baseline Characteristics and Treatments in HospitalTable 1 Baseline Characteristics and Treatments in Hospital
STEMI (n  1,958)
Radial
(n  955)
Femoral
(n  1,003)
Age, yrs 60 12.0 59 11.7
Age 75 yrs 123 (12.9) 106 (10.6)
Women 193 (20.2) 217 (21.6)
Diabetes 177 (18.5) 168 (16.7)
Previous MI 87 (9.1) 103 (10.3)
Previous PCI 57 (6.0) 66 (6.6)
Current smoker 414 (43.4) 415 (41.4)
Peripheral arterial disease 16 (1.7) 20 (2.0)
Treatment in hospital
Aspirin 953 (99.8) 998 (99.5)
Clopidogrel 935 (97.9) 985 (98.2)
Clopidogrel loading dose 300 mg* 448 (54.3) 427 (50.7)
UFH 674 (70.6) 657 (65.5)
LMWH 402 (42.1) 450 (44.9)
Fondaparinux 53 (5.5) 46 (4.6)
Bivalirudin 22 (2.3) 41 (4.1)
GP IIb/IIIa inhibitor 329 (34.5) 312 (31.1)
Fibrinolytic therapy 121 (12.7) 112 (11.2)
PPIs 338 (35.4) 381 (38.0)
Beta-blockers 834 (87.3) 889 (88.6)
ACE inhibitors 791 (82.8) 814 (81.2)
Angiotensin receptor antagonists 57 (6.0) 67 (6.7)
Statins 910 (95.3) 969 (96.6)
Calcium-channel blockers 105 (11.0) 97 (9.7)
Values are mean  SD or n (%). *STEMI: 825 in the radial group and 842 in the femoral group. N
ACE angiotensin-converting enzyme; GP glycoprotein; LMWH low molecular weight heparin; MI
NSTEACS  non–ST-segment acute coronary syndromes; STEMI  ST-segment elevation myocardial infadistributed variables) or nonparametric Wilcoxon sum rank
test (for non-normally distributed variables). All analyses
were by intention to treat (assignment to either radial or
femoral access). Outcomes of patients randomized to radial
versus femoral artery access were stratified according to
pre-randomization diagnosis STEMI or NSTEACS. Cu-
mulative event rates were determined from time-to-event
data and are displayed through the use of Kaplan-Meier
plots. Comparisons between groups were made using of the
log-rank test. Tests for interaction were performed to
determine whether there was heterogeneity in treatment
effect of radial versus femoral access site with pre-
randomization diagnosis (STEMI vs. NSTEACS). A mul-
tivariable analysis using a Cox proportional hazards model
was performed to examine whether the statistical interaction
between treatment and pre-randomization diagnosis on
mortality was independent of baseline variables, operator,
and center volume.
Results
We enrolled a total of 7,021 patients with ACS; 1,958 with
a pre-randomization diagnosis of STEMI and 5,063 pa-
tients with NSTEACS. Compared with patients with
NSTEACS, patients with STEMI were younger and more
NSTEACS (n  5,063)
p Value STEMI
vs. NSTEACSue
Radial
(n  2,552)
Femoral
(n  2,511)
p
Value
79 63 11.3 63 11.7 0.9274 0.0001
17 383 (15.0) 423 (16.8) 0.0739 0.0001
83 715 (28.0) 736 (29.3) 0.3087 0.0001
03 604 (23.7) 554 (22.1) 0.1740 0.0001
64 571 (22.4) 519 (20.7) 0.1399 0.0001
71 374 (14.7) 342 (13.6) 0.2906 0.0001
67 669 (26.2) 682 (27.2) 0.4468 0.0001
99 75 (2.9) 62 (2.5) 0.3030 0.0355
40 2,526 (99.0) 2,491 (99.2) 0.4045 0.0167
10 2433 (95.3) 2,373 (94.5) 0.1771 0.0001
22 760 (51.1%) 738 (49.0) 0.2346 0.1103
62 1,096 (42.9) 1,087 (43.3) 0.8055 0.0001
63 1,404 (55.0) 1,369 (54.5) 0.7232 0.0001
07 330 (12.9) 335 (13.3) 0.6657 0.0001
53 54 (2.1) 68 (2.7) 0.1696 0.0580
50 558 (21.9) 532 (21.2) 0.5571 0.0001
43 — — — —
41 712 (27.9) 716 (28.5) 0.6269 0.0001
47 2,270 (88.9) 2,241 (89.2) 0.7342 0.1904
64 1,755 (68.8) 1,725 (68.7) 0.9560 0.0001
83 320 (12.5) 319 (12.7) 0.8598 0.0001
72 2,399 (94.0) 2,320 (92.4) 0.0227 0.0001
58 550 (21.6) 526 (20.9) 0.5995 0.0001
S: 1,486 in the radial group and 1,507 in the femoral group.p
Val
0.26
0.11
0.43
0.30
0.38
0.57
0.37
0.59
0.28
0.63
0.14
0.01
0.21
0.33
0.02
0.11
0.30
0.23
0.37
0.33
0.51
0.13
0.33
STEAC
myocardial infarction; PCI percutaneous coronary intervention; PPIs proton pump inhibitors;
rction; UFH  unfractionated heparin.
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lower rates of previous diabetes, MI, and PCI. STEMI
patients had significantly greater use of glycoprotein IIb/IIIa
inhibitors, clopidogrel, and heparin, whereas fondaparinux
and bivalirudin were used more commonly in patients with
NSTEACS. Fibrinolytic therapy was used in 12% of pa-
tients with STEMI and in no patients with NSTEACS.
Characteristics of the randomized treatment groups were
well matched in each cohort with the exception of unfrac-
tionated heparin, which was used more commonly in
STEMI patients allocated to radial access, and bivalirudin,
which was used more commonly in STEMI patients to
allocated femoral access (Table 1).
Procedures and operator experience. STEMI patients
had much higher rates of PCI compared with NSTEACS
patients (85% vs. 59%, p  0.0001) (Table 2). In the
STEMI group, operators had significantly more experience
in radial artery access (median, 400 radial procedures/year)
than operators in the NSTEACS group (median of 326
radial procedures/year, p  0.0001). By contrast, femoral
artery experience was higher among operators performing
procedures in patients with NSTEACS cohort (median,
428 procedures/year) compared with operators in the
STEMI patients (300 procedures/year, p  0.0001). Total
Procedural Characteristics and Operator ExperienceTable 2 Procedural Characteristics and Operator Experience
Characteristic
STEMI
Radial
(n  955)
Femoral
(n  1,003) p
Coronary angiography 157 (16.4) 178 (17.7)
PCI 825 (86.4) 842 (83.9)
Primary PCI 702 (73.5) 749 (74.7)
Secondary PCI 253 (26.5) 254 (25.3)
Stent* 778 (94.3) 807 (95.8)
Bare-metal stent 608 (78.1) 642 (79.6)
1 Drug-eluting stent 184 (23.7) 180 (22.3)
CABG 22 (2.3) 34 (3.4)
Arterial sheath size, F†
5 69 (7.2) 26 (2.6) 
6 872 (91.4) 925 (92.7)
7 13 (1.4) 45 (4.5) 
Intra-aortic balloon pump 7 (0.7) 16 (1.6)
Fluoroscopy time 9.3 (6.0–15.0) 8.0 (5.0–13.0) 
Contrast use, ml 180 (150–220) 180 (140–220)
Primary PCI time intervals n  643 n  678
Door to PCI start 85 (54–175) 85 (50–160)
Door to PCI end 128 (89–221) 120 (80–200)
Randomization to PCI start 21 (13–33) 20 (11–30)
Randomization to PCI end 58 (44–80) 53 (40–73)
Operator experience, yrs
Radial cath or PCI 400 (225–750) 400 (210–720)
Femoral cath or PCI 300 (132–523) 300 (125–523)
Total PCI 300 (180–450) 300 (180–421)
Proportion radial, % 50 (33–80) 47 (30–80)
Values are n (%) or median (interquartile range). *As a proportion of patients undergoing PCI. †STE
in the femoral group.
CABG  coronary artery bypass graft; cath  catheterization; IQR  interquartile range; other abbreviPCI volume was similar between STEMI and NSTEACS
operators (median, 300 vs. 300 procedures/year). Drug-
eluting stents were used almost twice as frequently in
NSTEACS patients (44%) compared with STEMI pa-
tients (23%).
Procedural characteristics were well matched between the
radial versus femoral artery randomized groups with no
significant differences except for sheath sizes, which were
smaller in the radial group compared with the femoral group
and the use of drug-eluting stents in the NSTEACS
population, which was slightly more common among pa-
tients randomized to the radial approach (Table 2). There
were no significant differences in operator procedure volume
between the radial and femoral groups.
Primary and secondary outcomes. For the primary out-
come of death, MI, stroke or non-CABG–related major
bleeding, there was a significant interaction (p  0.025)
etween randomized treatment (radial or femoral artery
ccess) and pre-randomization diagnosis (STEMI or
STEACS) (Fig. 1, Table 3). We also found significant
nteractions for the secondary composite of death, MI, or
troke (p  0.011) and for mortality alone (p  0.001).
Among STEMI patients, the primary outcome occurred
n 3.1% of patients randomized to radial access compared
NSTEACS STEMI
vs.
NSTEACS
p Value
Radial
(n  2,552)
Femoral
(n  2,511) p Value
1,135 (44.5) 1,075 (42.8) 0.2328 0.0001
1,486 (58.2) 1,507 (60.0) 0.1959 0.0001
— — — —
— — — —
1,409 (94.8) 1,426 (94.6) 0.8132 0.5941
820 (58.2) 902 (63.3) 0.0058 0.0001
651 (46.2) 592 (41.5) 0.0119 0.0001
286 (11.2) 257 (10.2) 0.2638 0.0001
436 (17.1) 211 (8.4) 0.0001 0.0001
1,836 (72.1) 1,886 (75.2) 0.0136 0.0001
22 (0.9) 167 (6.7) 0.0001 0.1177
24 (0.9) 21 (0.8) 0.6931 0.2727
9.3 (5.1–15.0) 8.0 (4.0–13.0) .0001 0.0130
190 (140–250) 190 (150–250) 0.5463 0.0005
338 (165–516) 320 (160–477) 0.4697 .0001
420 (210–665) 436 (220–665) 0.8042 .0001
300 (190–400) 295 (190–400) 0.9303 0.2250
40 (20–65) 40 (20–65) 0.6355 .0001
in the radial group and 998 in the femoral group. NSTEACS: 2,545 in the radial group and 2,508Value
0.4427
0.1293
0.5553
—
0.1460
0.4935
0.5243
0.1495
0.0001
0.2955
0.0001
0.0767
.0001
0.2223
0.2097
0.0968
0.0160
0.0009
0.4152
0.5101
0.5074
0.4002
MI: 954ations as in Table 1.
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0.60; 95% CI: 0.38 to 0.94; p  0.026) (Fig. 1A, Table 3).
Compared with femoral access, radial access also reduced
the first secondary composite outcome of death, MI, or
stroke (2.7% vs. 4.6%; HR: 0.59; 95% CI: 0.36 to 0.95;
p  0.031). This benefit was driven mainly by a reduction
n mortality with radial artery access (1.3% vs. 3.2%; HR:
.39; 95% CI: 0.20 to 0.76; p  0.006), with similar rates
of MI and stroke (Fig. 2A, Table 3). The other secondary
outcome of non-CABG major bleeding occurred infre-
quently and was not significantly different between the
groups (Table 3).
Among patients with NSTEACS, the primary outcome
occurred in 3.8% randomized to radial artery intervention
compared with 3.5% randomized to femoral artery interven-
tion (HR: 1.11; 95% CI: 0.83 to 1.48; p  0.49) (Fig. 1B,
Table 3). There were no reductions in either of the 2
secondary outcomes or in any of the individual components
of the primary outcome (Table 3). Moreover, among
NSTEACS patients who underwent PCI, we found no
significant difference in the primary outcome between the
radial (3.63%, n  1,486) and femoral (3.38%, n  1,507)
groups (HR: 1.07; 95% CI: 0.73 to 1.57; p  0.73). In
patients with unstable angina (n 1,903; PCI rate: 53.9%),
the primary outcome was 2.40% in the radial group and
2.65% in the femoral group (HR: 0.90; 95% CI: 0.51 to
1.59), and there was a reduction in ACUITY major bleed-
ing (1.20% vs. 3.87%; HR: 0.31: 95% CI: 0.16 to 0.60).
Similarly, in patients with non–ST-segment elevation myo-
cardial infarction (n 3,160; PCI rate: 62.2%) , the primary
outcome was similar in the radial and femoral artery groups
(4.76% radial vs. 3.92% femoral; HR: 1.21; 95% CI: 0.87 to
1.70) with a reduction in ACUITY major bleeding (2.26%
Figure 1 Primary Outcome (Cardiovascular Death, Myocardial I
Non-Coronary Artery Bypass Graft–Related Major Blee
For the primary outcome, there was a significant interaction between access site a
with an interaction p value of 0.025. In patients with STEMI (A), radial artery acce
patients with NSTEACS (B), there was no significant difference between radial and
non–ST-segment elevation acute coronary syndrome; STEMI  ST-segment elevativs. 4.80%; HR: 0.47; 95% CI: 0.31 to 0.70).Other outcomes. PCI success rates were similar in the
radial and femoral groups in both STEMI and NSTEACS
patients. ACUITY major bleeding (defined as RIVAL
major bleeding  large hematomas  pseudoaneurysms
requiring closure) occurred less frequently in patients with
STEMI allocated to radial artery access (HR: 0.49; 95% CI:
0.28 to 0.84; p  0.009) as well as in patients with
NSTEACS (HR: 0.41; 95% CI: 0.29 to 0.58; p  0.0001),
without significant heterogeneity (Table 3). Similarly, major
vascular access site complications alone were reduced with
radial access in both STEMI and NSTEACS, with no
significant heterogeneity (Table 3). Access site crossover
was higher in the radial group compared with the femoral
group, and this was consistent in both STEMI and
NSTEACS cohorts.
Primary PCI. Among patients with STEMI undergoing
PCI, 1,451 patients (74%) received a primary PCI and 507
patients (26%) received a secondary PCI (i.e., 3% facilitated,
12% rescue, or 11% routine adjunctive). For the primary
outcome, there was no heterogeneity in treatment effect in
patients receiving a primary versus secondary PCI (interac-
tion p  0.79). Among patients undergoing primary PCI,
30-day mortality occurred in 1.4% of patients randomized
to radial access versus 3.07% randomized to femoral access
(HR: 0.46; 95% CI: 0.22 to 0.97; p  0.041). Major
vascular access site complications (1.4% vs. 4.0%; HR: 0.35;
p  0.005) and ACUITY-defined major bleeding (1.86%
vs. 4.68%; HR: 0.39; p  0.004) were substantially lower
with radial access in primary PCI patients. Overall time
from hospital presentation to PCI start was not significantly
different between the radial and femoral access groups
(Table 2). However, time from randomization to the end of
PCI was 5 min longer in the radial artery group (58 min vs.
tion, Stroke, or
in Patients With STEMI and NSTEACS
ion (radial or femoral) and acute coronary syndrome type (STEMI or NSTEACS)
uced the primary outcome compared with femoral artery access, whereas in
ral artery access. CI  confidence interval; HR  hazard ratio; NSTEACS 
cardial infarction.nfarc
ding)
llocat
ss red
femo
on myo53 min, p  0.0009).
a
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the interaction between pre-randomization diagnosis
(STEMI vs. NSTEACS) and randomized treatment (radial
vs. femoral access) remained highly significant (p  0.0001),
fter adjustment for baseline variables, center radial volume,
nd operator radial experience (Table 4). Analyses focusing on
ivalirudin revealed no significant interaction in the primary
utcome between access site allocation and a bivalirudin-based
nticoagulation strategy and one that did not include bivaliru-
in in the overall cohort of STEMI plus NSTEACS patients
p for interaction  0.2823). Similarly, among patients with
Efficacy and Safety Outcomes in Patients With STEMI and NSTEACTable 3 Efficacy and Safety Outcomes in Patients With STEMI
STEMI
Radial
(n  955)
Femoral
(n  1,003) HR (95% CI) p Va
Death, MI, stroke or
non-CABG
major bleed
(primary
outcome)
30 (3.14) 52 (5.19) 0.60 (0.38–0.94) 0.0
Death, MI or stroke
(secondary
outcome)
26 (2.72) 46 (4.59) 0.59 (0.36–0.95) 0.0
Non-CABG major
bleed
(secondary
outcome)
8 (0.84) 9 (0.91) 0.92 (0.36–2.39) 0.8
Access site
related
1 (0.10) 2 (0.20) 0.53 (0.05–5.84) 0.6
Non–access site
related
7 (0.74) 7 (0.71) 1.04 (0.36–2.95) 0.9
ACUITY major bleed 19 (1.99) 41 (4.10) 0.49 (0.28–0.84) 0.0
Access site
related
12 (1.26) 34 (3.39) 0.37(0.19–0.72) 0.0
Non–access site
related
7 (0.74) 7 (0.71) 1.04 (0.36–2.95) 0.9
Death 12 (1.26) 32 (3.19) 0.39 (0.20–0.76) 0.0
MI 11 (1.16) 18 (1.82) 0.63 (0.30-–1.33) 0.2
Stroke 5 (0.53) 4 (0.40) 1.30 (0.35–4.84) 0.6
Major vascular
access site
complication
12 (1.26) 35 (3.49) 0.36 (0.19–0.70) 0.0
PCI success* 789 (95.7) 806 (95.8) 1.00 (0.91–1.10) 1.0
Access site
crossover
51 (5.34) 16 (1.60) 3.32 (1.89–5.82) 0.0
Minor bleed 33 (3.48) 22 (2.21) 1.59 (0.93–2.72) 0.0
TIMI major bleed 8 (0.84) 6 (0.61) 1.37 (0.48–3.96) 0.5
Any blood
transfusion
11 (1.16) 15 (1.51) 0.76 (0.35–1.66) 0.4
Death, MI, stroke or
ACUITY major
bleed
40 (4.19) 82 (8.18) 0.51 (0.35–0.74) 0.0
Stent thrombosis* 4 (0.49) 12 (1.44) 0.34 (0.11–1.07) 0.0
Definite stent
thrombosis*
3 (0.37) 6 (0.72) 0.51 (0.13–2.04) 0.3
Probable stent
thrombosis*
1 (0.12) 6 (0.72) 0.18 (0.02–1.45) 0.1
Values are n (%). *Among patients who had PCI: STEMI: 825 in the radial group and 842 in the fe
CI  confidence interval; HR  hazard ratio; TIMI  Thrombolysis In Myocardial Infarction; otheSTEMI, there was also no significant interaction between abivalirudin-based strategy and access site allocation (p for
interaction  0.5519).
Other independent predictors of death included older
age, diabetes, current smoking, and PCI performed at a
low- (compared with a high-) volume radial center.
Among patients with STEMI, those who died by day 30
were more likely to have experienced a major bleeding event
compared with those who survived (11.0% vs. 1.0%, p 
0.0001) (Table 5). Other factors significantly associated
with death included femoral artery access site allocation,
older age, female sex, CABG surgery after randomization,
NSTEACS
NSTEACS
Interaction
p Value
Radial
(n  2,552)
Femoral
(n  2,511) HR (95% CI) p Value
98 (3.84) 87 (3.46) 1.11 (0.83–1.48) 0.491 0.025
86 (3.37) 68 (2.71) 1.25 (0.91–1.71) 0.176 0.011
16 (0.63) 24 (0.96) 0.66 (0.35–1.23) 0.190 0.557
4 (0.16) 10 (0.40) 0.39 (0.12–1.26) 0.116 0.838
12 (0.47) 14 (0.56) 0.84 (0.39–1.82) 0.664 0.753
47 (1.84) 112 (4.46) 0.41 (0.29–0.58) 0.001 0.624
36 (1.41) 98 (3.90) 0.36 (0.25–0.53) 0.0001 0.955
11 (0.43) 14 (0.56) 0.77 (0.35–1.70) 0.521 0.656
32 (1.25) 19 (0.76) 1.66 (0.94–2.92) 0.082 0.001
49 (1.92) 47 (1.87) 1.03 (0.69–1.53) 0.903 0.269
15 (0.59) 10 (0.40) 1.48 (0.67–3.30) 0.335 0.864
37 (1.45) 96 (3.82) 0.38 (0.26–0.55) 0.001 0.885
1415 (95.3) 1429 (94.8) 1.01 (0.94–1.09) 0.813 0.924
214 (8.39) 54 (2.15) 3.94 (2.92–5.31) 0.001 0.606
67 (2.63) 96 (3.83) 0.68 (0.50–0.93) 0.016 0.008
11 (0.43) 13 (0.52) 0.83 (0.37–1.86) 0.658 0.457
88 (3.46) 83 (3.31) 1.05 (0.78–1.41) 0.765 0.446
127 (4.98) 174 (6.93) 0.71 (0.56–0.89) 0.003 0.129
12 (0.81) 14 (0.93) 0.87 (0.40–1.87) 0.713 0.187
5 (0.34) 10 (0.66) 0.51 (0.17–1.48) 0.213 0.989
7 (0.47) 5 (0.33) 1.41 (0.45–4.44) 0.558 0.089
group. NSTEACS: 1,486 in then radial group and 1,507 in the femoral group.
viations as in Tables 1 and 2.Sand
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moralunsuccessful PCI, stent thrombosis, and new MI (Table 5).
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RIVAL is the largest randomized comparison of radial and
femoral artery access in patients with STEMI as well as in
those with NSTEACS. In patients with STEMI, radial
artery access significantly reduced the primary outcome and
the secondary outcome of death, MI, or stroke as well as
all-cause mortality. In patients presenting with NSTEACS,
we found no significant differences in any of these out-
comes. In both STEMI and NSTEACS patients, radial
access reduced major vascular access site complications and
major bleeding as defined by the ACUITY definition.
Figure 2 Death in Patients With STEMI and NSTEACS
For death, there was a significant interaction between access site allocation (radia
tion p value of 0.001. In patients with STEMI (A), radial artery access reduced the
(B), there was no significant difference in mortality between radial and femoral art
Multivariable Predictors of Mortality in RIVALTable 4 Multivariable Predictors of Mortalit
Variable
Access site (radial vs. femoral) in STEMI cohort
Access site (radial vs. femoral) in NSTEACS cohort
ACS type (STEMI vs. NSTEACS) in femoral group
ACS type (STEMI vs. NSTEACS) in radial group
Access site  ACS type interaction
Operator radial volume
Tertile 2 vs. tertile 1
Tertile 3 vs. tertile 1
Center radial volume
Tertile 2 vs. tertile 1
Tertile 3 vs. tertile 1
Age (per 1-yr increase)
Sex (men vs. women)
Diabetes vs. no diabetes
Previous MI vs. no previous MI
Previous PCI vs. no previous PCI
Smoker vs. non- or previous smoker
PAD vs. no PAD
Body mass index
Baseline hemoglobinACS  acute coronary syndromes; PAD  peripheral artery disease; other abIn STEMI patients, the reduction in the primary and
secondary composite outcomes was driven mainly by a
reduction in mortality with a directionally consistent reduc-
tion in MI. No such benefit was observed in patients with
NSTEACS. In the multivariable analysis, this interaction
between pre-randomization ACS type and access-site allo-
cation remained highly significant, even after adjustment for
baseline variables, operator radial experience, and center
radial volume. There are several plausible reasons why a
differential response to radial versus femoral access on
mortality might occur. First, within the first 30 days,
STEMI patients are at higher risk of mortality compared
moral) and acute coronary syndrome type (STEMI or NSTEACS) with an interac-
lity compared with femoral artery access, whereas in patients with NSTEACS
cess. Abbreviations as in Figure 1.
IVAL
HR 95% CI p Value
0.266 0.127–0.561 0.0005
1.680 0.951–2.965 0.0737
5.364 2.972–9.682 0.0001
0.851 0.400–1.812 0.6753
— — 0.0001
1.486 0.783–2.818 0.2256
1.508 0.722–3.149 0.2746
0.711 0.377–1.339 0.2906
0.524 0.243–1.129 0.0987
1.086 1.061–1.111 0.0001
0.855 0.530–1.379 0.5212
1.862 1.188–2.919 0.0067
1.111 0.614–2.009 0.7274
0.631 0.281–1.414 0.2630
1.995 1.207–3.299 0.0071
1.446 0.620–3.375 0.3935
0.970 0.923–1.019 0.2271
0.895 0.791–1.013 0.0780l or fe
morta
ery acy in Rbreviations as in Tables 1 and 3.
p
s
(
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the femoral access site groups), in whom nonfatal ischemic
events (i.e., new MI) are more common (21,22). Therefore,
if a reduction in bleeding-related complications was associ-
ated with lower mortality, it might most likely be detected
in the STEMI group of patients. Second, STEMI patients
generally undergo a much higher rate of PCIs (90%)
compared with NSTEACS patients (50% to 60%), exposing
them to a higher frequency of access site complications.
Third, STEMI patients are often treated with more potent
initial and subsequent antiplatelet and antithrombotic ther-
apies (as well as fibrinolytic therapy) compared with patients
with NSTEACS. Therefore, the risk-adjusted rate of bleed-
ing (particularly access-site bleeding) is higher, making the
association between bleeding and mortality more readily
detectable in this population.
In RIVAL, we observed substantially lower rates of major
vascular access site complications and ACUITY-defined
bleeding with radial access in both the STEMI and
NSTEACS cohorts. The rate of bleeding using the more
conservative RIVAL study definition, which excluded major
vascular access site complications (unless they led to death,
hemoglobin decrease of 5 g/dl, blood transfusion of 2
units, or surgery), was very low (1%), and consequently no
difference was found between the 2 groups. Despite this, we
found much higher 30-day mortality rates among those
patients who had a non-CABG–related major bleeding
event compared with those who did not in both the STEMI
and NSTEACS populations, irrespective of whether the
RIVAL or ACUITY bleeding definition was used. One
ossibility is that in the STEMI population, operators were
Characteristics of STEMI Patients Who Died Versus Those Who SuTable 5 Characteristics of STEMI Patients Who Died Versus Th
Characteristic Overall (N  1,958) Patie
Age, yrs 60 12
Diabetes 345 (17.6)
Previous PCI or CABG 129 (6.6)
Female 410 (20.9)
Access site randomization to radial 955 (48.8)
Crossover from radial to femoral (yes) 51 (5.3)
Access site randomization to femoral 1,003 (51.2)
Crossover from femoral to radial (yes) 16 (1.6)
Non-CABG major bleed 17 (0.9)
Any major bleed 25 (1.3)
Non-CABG blood transfusion 13 (0.7)
Minor bleed* 55 (2.8)
CABG surgery after randomization 56 (2.9)
Vascular access complication 47 (2.4)
ACUITY major bleed 60 (3.1)
Non-CABG ACUITY major bleed Same
PCI success* 1,595 (95.7)
Stent thrombosis (definite or probable)* 16 (1.0)
MI after randomization 29 (1.5)
Stroke after randomization 9 (0.5)
Values are mean  SD or n (%). *Among patients who had PCI: 32 died, 1,635 survived.
Abbreviations as in Tables 1 and 2.ignificantly more experienced, as were centers in the perfor- amance of transradial intervention, compared with the
NSTEACS population. There is clearly a learning curve for
radial artery intervention, and there may be a threshold before
significant benefits with this procedure are observed. Despite
this, in a multivariable model of predictors of mortality in
RIVAL, the interaction between pre-randomization ACS type
and access site allocation remained highly significant, even after
adjustment for baseline variables, operator and center experi-
ence, indicating that it was independent of operator and center
radial access experience.
Our study has several strengths. It is the largest random-
ized comparison of radial and femoral access site approaches
in patients with STEMI. The trial consisted of experienced
operators and high-volume radial access site centers. Be-
cause RIVAL included both STEMI and NSTEACS
patients in large numbers, it allowed us to compare and
contrast the relative benefits and risks of radial intervention
in these patients and explore reasons for a possible differ-
ential response.
Study limitations. Limitations of our analysis also need to
be considered. The overall result of RIVAL on the primary
outcome was neutral, so it may not be appropriate to look at
subgroups because the overall result of the trial may be the
most reliable (23,24). Replication in independent random-
ized trials would strengthen the conclusions of our analysis.
In the RIFLE-ACS (Radial Versus Femoral Investigation
in ST Elevation Acute Coronary Syndrome) trial of 1,001
patients with STEMI randomized to radial or femoral
intervention, rates of bleeding due to access site complica-
tions (12.2% vs. 7.8%, p  0.026) and subsequent mortality
9.2% vs. 5.2%, p  0.020) were lower using the radial
at Day 30Who Survived at Day 30
ho Died (n  44) Patients Who Survived (n  1,914) p Value
4 12 59 12 0.0001
2 (27.3) 333 (17.4) 0.0892
2 (4.5) 127 (6.6) 0.5806
6 (36.4) 394 (20.6) 0.0110
2 (27.3) 943 (49.3) 0.0039
2 (16.7) 49 (5.2) 0.0791
2 (72.7) 971 (50.7) 0.0039
0 (0.0) 16 (1.6) —
4 (9.1) 13 (0.7) 0.0001
5 (11.4) 20 (1.0) 0.0001
2 (4.5) 11 (0.6) 0.0013
1 (2.3) 54 (2.8) 0.8276
4 (9.1) 52 (2.7) 0.0121
0 (0.0) 47 (2.5) —
4 (9.1) 56 (2.9) 0.0190
5 (78.1) 1,570 (96.0) 0.0001
8 (25.0) 8 (0.5) 0.0001
4 (9.1) 25 (1.3) 0.0001
4 (9.1) 5 (0.3) 0.0001rvivedose
nts W
6
1
1
1
3
2rtery approach (27). Data from this independent study are
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in RIVAL. Second, there were exceedingly few RIVAL-
defined major bleeding events in this trial (1%). Although
we demonstrated a much higher mortality rate in patients
who experienced a major bleed compared with those who
did not, the low frequency of events may have impeded our
ability to determine whether a reduction in major bleeding
could have affected longer-term mortality. Bleeding is an
outcome that is definition dependent (25,26). Using the
ACUITY definition of major bleeding, there were substan-
tial reductions in bleeding in both the STEMI and
NSTEACS cohorts in RIVAL. Third, because centers
participating in RIVAL were highly experienced in the
radial technique, similar outcomes may not apply in centers
performing lower volumes. Fourth, the ACUITY definition
of major bleeding used in RIVAL included large hematoma
(defined as large if it prolonged hospitalization), which
differs slightly from the ACUITY definition of hematoma
(5 cm). Finally, unfractionated heparin was the anticoag-
ulation strategy most commonly used in RIVAL, with few
patients receiving bivalirudin. However, in the HORIZON-AMI
(Harmonizing Outcomes With Revascularization and
Stents in Acute Myocardial Infarction Trial), there was a
consistent benefit of the radial technique in patients receiv-
ing bivalirudin as well as those receiving heparin plus
glycoprotein IIb/IIIa inhibitors (28).
Conclusions
In this large randomized comparison, radial artery access
reduced the primary outcome and mortality in patients
presenting with STEMI. There was no such benefit in
patients presenting with NSTEACS. This interaction be-
tween ACS type and access site allocation was independent
of operator radial experience and center radial volume.
These data suggest that radial artery access might be the
preferred option in patients with STEMI.
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